Article Text

SP0133 Systemic Sclerosis and Myositis
  1. U. Mueller-Ladner1
  1. 1Rheumatology, University of Giessen, Bad Nauheim, Germany


Both rare connective tissue diseases, systemic sclerosis and myositis, have been addressed as interesting fields of research and numerous novel aspects have been published in the past year. Epidemiologic data from the large EUSTAR group could show the detailed real world profile of around 10.000 patients with systemic sclerosis. In addition, distinct novel aspects such as cardiovascular morbidity, osteologic dysfunctio and gender-related manifestations of the disease were addressed. Parallel to the acquisition of these data, novel classification criteria for SSc were established. Novel therapeutic approaches included first results from stem cell transplantation but also the effects of immunosuppressants such as mycophenolate on skin fibrosis or neuromodulators on digital ulcers. In SSc but also in myositis, the search for biomarkers and functional autoantibodies continued and led to few but important results. Therapeutic research for myositis reevaluated the current immunomodulators including intravenous immunoglobulins but also novel approaches such as rituximab, the latter with promising results.

Disclosure of Interest None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.